Literature DB >> 28600142

Nectin-4 is a breast cancer stem cell marker that induces WNT/β-catenin signaling via Pi3k/Akt axis.

Sumit Siddharth1, Kunal Goutam2, Sarita Das1, Anmada Nayak1, Deepika Nayak1, Chinmayee Sethy1, Michael D Wyatt3, Chanakya Nath Kundu4.   

Abstract

Nectin-4 is well known as a junction protein. Recent reports have implicated it in cancer, but there has been little exploration of its functional significance in metastasis and cancer stem cells. Here, using the breast cancer metastasis model system, we report Nectin-4 is a marker for breast cancer stem cells (BCSCs) and provide experimental evidence suggesting that it utilizes WNT/β-Catenin signaling via Pi3k/Akt axis for self renewal of BCSCs. In vitro, in vivo, ex vivo and clinical pathological data showed upregulated Nectin-4 in breast cancer metastasis and WNT/β-Catenin signaling. Nectin-4 depletion inhibited EMT, metastasis, invasion, and the WNT/β-Catenin pathway; conversely, Nectin-4 overexpression in null cells upregulated EMT and metastasis and also induced WNT/β-Catenin signaling via Pi3k/Akt axis, which in turn, controls cancer stem cell proliferation. Induced Nectin-4 was observed in breast tumor patient samples and in breast tumor metastases to axillary lymph nodes, which indicated that Nectin-4 is not only a BCSC marker but also a breast cancer metastasis marker. The current study provides clear evidence that Nectin-4 is a BCSC marker and is responsible for breast cancer metastasis.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Metastasis; Nectin-4; Pi3k/Akt; WNT/β-catenin

Mesh:

Substances:

Year:  2017        PMID: 28600142     DOI: 10.1016/j.biocel.2017.06.007

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  26 in total

1.  Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse.

Authors:  Chinmayee Sethy; Kunal Goutam; Deepika Nayak; Rajalaxmi Pradhan; Sefinew Molla; Subhajit Chatterjee; Niranjan Rout; Michael D Wyatt; Satya Narayan; Chanakya Nath Kundu
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

Review 2.  The biology and rationale of targeting nectin-4 in urothelial carcinoma.

Authors:  Elisabeth I Heath; Jonathan E Rosenberg
Journal:  Nat Rev Urol       Date:  2020-11-25       Impact factor: 14.432

3.  Analysis of Protein-Protein Interactions Identifies NECTIN2 as a Target of N,N-Bis (5-Ethyl-2-hydroxybenzyl) Methylamine for Inhibition of Lung Cancer Metastasis.

Authors:  Sunisa Thongsom; Nithikoon Aksorn; Korrakod Petsri; Sittiruk Roytrakul; Nicharat Sriratanasak; Worawat Wattanathana; Pithi Chanvorachote
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

Review 4.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

Review 5.  Nectin-4: a Novel Therapeutic Target for Skin Cancers.

Authors:  Hiroki Hashimoto; Yuka Tanaka; Maho Murata; Takamichi Ito
Journal:  Curr Treat Options Oncol       Date:  2022-03-21

6.  Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.

Authors:  Anmada Nayak; Sarita Das; Deepika Nayak; Chinmayee Sethy; Satya Narayan; Chanakya Nath Kundu
Journal:  Cell Oncol (Dordr)       Date:  2019-01-03       Impact factor: 6.730

Review 7.  Breast cancer stem cells: A review of their characteristics and the agents that affect them.

Authors:  Naing L Shan; Yoosub Shin; Ge Yang; Philip Furmanski; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2021-01-11       Impact factor: 4.784

Review 8.  Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells.

Authors:  Saghar Yousefnia; Farzad Seyed Forootan; Shiva Seyed Forootan; Mohammad Hossein Nasr Esfahani; Ali Osmay Gure; Kamran Ghaedi
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

Review 9.  Antibody-Drug Conjugates in Bladder Cancer.

Authors:  Panagiotis J Vlachostergios; Christopher D Jakubowski; Muhammad J Niaz; Aileen Lee; Charlene Thomas; Amy L Hackett; Priyanka Patel; Naureen Rashid; Scott T Tagawa
Journal:  Bladder Cancer       Date:  2018-07-30

Review 10.  Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.

Authors:  Jeffrey L Wong; Jonathan E Rosenberg
Journal:  Expert Opin Biol Ther       Date:  2021-05-24       Impact factor: 5.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.